932750-29-3

Basic information

• Product Name: Ethyl (E)-2-cyano-3-ethoxycrotonate
• Synonyms: Ethyl (E)-2-cyano-3-ethoxycrotonate;(E)-ethyl 2-cyano-3-ethoxybut-2-enoate
• CAS NO: 932750-29-3
• Molecular Formula: C9H13NO3
• Molecular Weight: 183.2
• Mol File: 932750-29-3.mol

Chemical Properties

• Melting Point: 71-73°
• Boiling Point: 304.6°C at 760 mmHg
• Flash Point: 132°C
• Appearance: /
• Density: 1.055g/cm³
• Vapor Pressure: 0.000863mmHg at 25°C
• Refractive Index: 1.453
• CAS DataBase Reference: Ethyl (E)-2-cyano-3-ethoxycrotonate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl (E)-2-cyano-3-ethoxycrotonate(932750-29-3)
• EPA Substance Registry System: Ethyl (E)-2-cyano-3-ethoxycrotonate(932750-29-3)

Safety Data

• RIDADR: UN3439/PG:III/Hazard Class:6.1
• HazardClass: 6.1
• PackingGroup: III
• Hazardous Substances Data: 932750-29-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl (E)-2-cyano-3-ethoxycrotonate is utilized as an intermediate in the synthesis of pharmaceuticals, playing a crucial role in the development of new drugs. Its unique structure and reactivity allow for the creation of complex organic molecules that can be tailored for specific therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, Ethyl (E)-2-cyano-3-ethoxycrotonate is employed as a precursor in the production of insecticides and herbicides. Its involvement in the synthesis of these compounds helps to develop more effective and targeted pest control solutions for agricultural use.
Used in Organic Chemistry Research:
Ethyl (E)-2-cyano-3-ethoxycrotonate is also used in the field of organic chemistry research, where its unique properties are explored for potential applications in the synthesis of novel compounds and the advancement of chemical reactions and processes.

InChI:InChI=1/C9H13NO3/c1-4-12-7(3)8(6-10)9(11)13-5-2/h4-5H2,1-3H3/b8-7+

Upstream product

• 78-39-7 Triethyl orthoacetate 
• 105-56-6 ethyl 2-cyanoacetate 
• 186581-53-3 diazomethane 
• 94-05-3 ethyl (ethoxymethylene)cyanoacetate 
• 75-03-6 ethyl iodide 

Downstream Products

• 82114-04-3 4-hydroxy-6-methyl-2-phenylpyrimidine-5-carbonitrile 
• 288251-54-7 ethyl 5-amino-1-(4-fluorophenyl)-3-methyl-1H-pyrazole-4-carboxylate 
• 34605-62-4 ethyl 5-amino-1,3-dimethyl-1H-pyrazole-4-carboxylate 
• 86474-52-4 ethyl (Z)-2-cyano-3-(2-methoxyanilino)but-2-enoate 
• 86474-50-2 Ethyl 3-N-o-chloroanilino-2-cyanocrotonate 
• 288250-03-3 N-[3-cyano-4-(4-hydroxypiperidin-1-yl)phenyl]-N-[1-(4-fluorophenyl)-3-methylpyrazol-4-ylcarbonyl]glycine 
• 288250-06-6 N-[3-cyano-4-neopentyloxypheny]-N-[1-(2,4-difluorophenyl)-3-methylpyrazol-4-ylcarbonyl]glycine 
• 1418313-48-0 ethyl N-(3-cyano-4-neopentyloxyphenyl)-N-[1-(4-fluorophenyl)-5-methylpyrazol-4-ylcarbonyl]glycine 
• 288249-69-4 N-(3-cyano-4-neopentyloxyphenyl)-N-[1-(4-fluorophenyl)-5-methylpyrazol-4-ylcarbonyl]glycine 
• 288249-49-0 N-(3-cyano-4-neopentyloxyphenyl)-N-[1-(4-fluorophenyl)-3-methylpyrazol-4-ylcarbonyl]glycine 
• 288249-85-4 N-[3-cyano-4-(4-hydroxypiperidin-1-yl)phenyl]-1-(4-fluorophenyl)-3-methylpyrazole-4-carboxamide 
• 288249-39-8 N-(3-cyano-4-neopentyloxyphenyl)-1-(4-fluorophenyl)-3-methylpyrazole-4-carboxamide 
• 288249-48-9 N-(3-cyano-4-neopentyloxyphenyl)-1-(4-fluorophenyl)-N,3-dimethylpyrazole-4-carboxamide 
• 288249-53-6 N-(3-bromo-4-neopentyloxyphenyl)-1-(4-fluorophenyl)-3-methylpyrazole-4-carboxamide 

Relevant articles and documents

Aromatic ring dioxane quinazoline or quinoline compound, composition and application of aromatic ring dioxane quinazoline or quinoline compound

The invention relates to a novel compound serving as an inhibitor of kinase such as TRK, c-MET, AXL, MER and/or VEGFR2, a composition and application of the novel compound. Specifically, the inventionprovides a compound (as shown in formula (1)) or an isomer, a solvate, a hydrate, a pharmaceutically acceptable salt and a prodrug thereof, and a pharmaceutical composition containing the compound, wherein the compound has the activity of strongly inhibiting kinase such as TRK, c-MET, AXL, MER and/or VEGFR2. The invention further discloses application of the compound or the pharmaceutical composition in preparation of a medicine. The medicine is used for treating autoimmune diseases or cancers.

PHOSPHONATE CONJUGATES AND USES THEREOF

Phosphonate conjugates, preferably, bisphosphonate conjugates; methods of inhibiting Ron receptor tyrosine kinase and methods of treatment of bone destruction due to cancer or other conditions utilizing the provided phosphonate conjugates.

COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLIC DISEASE

Described herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as Cyp8b1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for diabetes and cardiovascular disease.

INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE

The present disclosure discloses compounds capable of modulating the activity of α- amino-β-carboxymuconic acid semialdehyde decarboxylase (ACMSD), which are useful for the prevention and/or the treatment of diseases and disorders associated with defects in NAD+ biosynthesis, e.g., metabolic disorders, neurodegenerative diseases, chronic inflammatory diseases, kidney diseases, and diseases associated with ageing. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament.

SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS

The present application relates to substituted fused heteroaryl and heterocyclic compounds, useful as nicotinamide adenine dinucleotide phosphate oxidase inhibitors (NADPH oxidase inhibitors), processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment or prevention of various diseases, conditions and/or disorders mediated by NADPH oxidase. (Formula I)

Pyrazolo[3,4-d]pyrimidine derivatives containing a Schiff base moiety as potential antiviral agents

A series of pyrazolo[3,4-d]pyrimidine derivatives containing a Schiff base moiety were synthesized, characterised, and evaluated for their activity against tobacco mosaic virus (TMV). Biological assays indicated that several of the derivatives exhibited significant activity against TMV. In particularly, compounds 5y and 5aa displayed excellent inactivating activity against TMV, with half maximal effective concentration (EC50) values of 70.3 and 53.65 μg/mL, respectively, which were much better than that of ribavirin (150.45 μg/mL), and 5aa was superior to ningnanmycin (EC50 = 55.35 μg/mL). Interactions of compounds 5y and 5aa with TMV coat protein (TMV-CP) were investigated using microscale thermophoresis and molecular docking. Compounds 5y and 5aa displayed strong binding capability to TMV-CP with dissociation constant (Kd) values of 22.6 and 9.8 μM, respectively. These findings indicate that pyrazolo[3,4-d]pyrimidine derivatives containing a Schiff base may be potential antiviral agents.

The pyrazole derivative or its salt in a pharmaceutical composition containing them

PROBLEM TO BE SOLVED: To provide a novel compound and a pharmaceutical composition useful for treatment and/or prevention of HIV virus infections.SOLUTION: Provided is a pyrazole derivative represented by the general formula (I) or a salt thereof (in the

CARM1 INHIBITORS AND USES THEREOF

Provided herein are compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X, R1, R2a, R2b, R2c, R2d, are as defined herein, and Ring HET is an optionally substituted 6,5-bicyclic heteroaryl ring system comprising 2 to 5 nitrogen atoms, inclusive, wherein the point of attachment is provided on the 6-membered ring of the 6,5-bicyclic heteroaryl ring system, and wherein the 6-membered ring is further substituted with a group of formula -L1-R3, wherein L1 and R3 are as defined herein. Compounds of the present invention are useful for inhibiting CARM1 activity. Methods of using the compounds for treating CARM1-mediated disorders are also described.

Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase

A novel series of 3-quinoline carboxamides has been discovered and optimized as selective inhibitors of the ataxia telangiectasia mutated (ATM) kinase. From a modestly potent HTS hit (4), we identified molecules such as 6-[6-(methoxymethyl)-3-pyridinyl]-4-{[(1R)-1-(tetrahydro-2H-pyran-4-yl)ethyl]amino}-3-quinolinecarboxamide (72) and 7-fluoro-6-[6-(methoxymethyl)pyridin-3-yl]-4-{[(1S)-1-(1-methyl-1H-pyrazol-3-yl)ethyl]amino}quinoline-3-carboxamide (74) as potent and highly selective ATM inhibitors with overall ADME properties suitable for oral administration. 72 and 74 constitute excellent oral tools to probe ATM inhibition in vivo. Efficacy in combination with the DSB-inducing agent irinotecan was observed in a disease relevant model.

A Michael Equilibration Model to Control Site Selectivity in the Condensation toward Aminopyrazoles

A Michael equilibration model is presented to provide for site-selective pyrazole condensations between alkoxyacrylonitriles and hydrazines. Both pyrazole isomers were accessed with high selectivity by employment of kinetically or thermodynamically controlled conditions. Substrate scope and identification of Michael intermediates, as well as competitive pathways, support the presented mechanistic proposal. Sandmeyer derivatization provided site-selective access to fully substituted pyrazoles.